The current situation of Sars-Cov-2 pandemic generates fears in the general population. Among patients receiving long-term immunomodulatory drugs, especially in the context of auto-immune diseases, there may be legitimates interrogations about the appropriateness of continuing treatment, without modification, in the current context. Most patients with Juvenile Rheumatoid Arthritis benefit from long-term immunmodulatory therapy (DMARD - disease modifying anti-rheumatic drug), more or less combined with regular use of non-steroidal anti-inflammatory drugs (NSAIDs) or corticosteroids.The present study will characterize this issue by defining the proportion of patients whose usual treatment of Rheumatoid Arthritis has been modified in relation to the actual sanitary crisis.

Inclusion Criteria:

• Rheumatoid arthritis satisfying ACR/EULAR criteria
• Ongoing DMARD therapy

Exclusion Criteria:

• Inhability to consent

Rheumatoid arthritis patients with ongoing DMARD therapy.

All collected data that underlie results in a publication

Data will be available beginning one month and ending five years following the end study

Data access requests will be reviewed by the internal committee of Brest UH. Requestors will be required to sign and complete a data access agreement.